Study to Evaluate NA-NOSE for Monitoring and Detecting Recurrence in Early Stage Lung Cancer

Inclusion Criteria: * Patients must either have histologic or pathologically confirmed non-small cell lung cancer (NSCLC) or suspicious nodules/lesions which are going to be surgically resected before they are pathologically confirmed * Patients must have stage I or II disease based on the parameters for staging NSCLC found in the American Joint Committee on Cancer (AJCC) cancer staging handbook seventh edition * Patients must be deemed to be eligible candidates for either surgery or stereotactic radiation * Stereotactic radiation treatment of stage I disease or adjuvant chemotherapy is allowed at the discretion of treating physician for the participating subject * Patients who will have surgical resections must consent to the use of post-surgery tumor samples for correlative molecular studies * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * Ability to travel to appointments and willingness to participate in this study * Ability to understand and willingness to sign a consent and Health Insurance Portability and Accountability Act (HIPAA) authorization form Exclusion Criteria: * Patients who have had a prior lung cancer within the last five years from the current diagnosis * Patients having a prior malignancy within the past 3 years other than resected of basal or squamous cell carcinoma of the skin, any in situ malignancy, or low-risk prostate cancer after curative therapy * Patients with any prior systemic therapy for the current diagnosis of lung cancer * Patients with a diagnosis of advanced stage disease (stage III or IV) * Patients who are unable to comply with study and/or follow up procedures * Patients who have uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements * Patients who are pregnant or are breast feeding